UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1080-1087

2018

Volltextzugriff (PDF)

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2015-08, Vol.373 (8), p.737-746

2015

Volltextzugriff (PDF)

The distribution of esophageal cancer patients enrolled in care at the Uganda Cancer Institute by sub-regions, districts and ethnicity

African health sciences, 2024-03, Vol.24 (1), p.198-205

2024

Volltextzugriff (PDF)

Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute

African health sciences, 2021-03, Vol.21 (1), p.67-74

2021

Volltextzugriff (PDF)

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

Clinical cancer research, 2009-10, Vol.15 (19), p.6277-6283

2009

Volltextzugriff (PDF)

Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer

Clinical cancer research, 2004-01, Vol.10 (1), p.96-100

2004

Volltextzugriff (PDF)

Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda

Ecancermedicalscience, 2023, Vol.17, p.1576-1576

2023

Volltextzugriff (PDF)

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

JCO clinical cancer informatics, 2023-06, Vol.7 (7), p.e2200164

2023

Volltextzugriff (PDF)

Upper gastrointestinal diseases in patients for endoscopy in South-Western Uganda

African health sciences, 2015-09, Vol.15 (3), p.959-966

2015

Volltextzugriff (PDF)

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

Journal of clinical oncology, 2006-04, Vol.24 (10), p.1485-1488

2006

Volltextzugriff (PDF)

Phase 2 Trial of Pemetrexed Disodium and Gemcitabine in Advanced Urothelial Cancer (E4802) : A Trial of the Eastern Cooperative Oncology Group

Cancer, 2008-06, Vol.112 (12), p.2671-2675

2008

Volltextzugriff (PDF)

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

Investigational new drugs, 2012-02, Vol.30 (1), p.364-367

2012

Volltextzugriff (PDF)

A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors

Investigational new drugs, 2011-02, Vol.29 (1), p.126-130

2011

Volltextzugriff (PDF)

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

Investigational new drugs, 2009-10, Vol.27 (5), p.453-460

2009

Volltextzugriff (PDF)

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

Investigational new drugs, 2008-08, Vol.26 (4), p.355-362

2008

Volltextzugriff (PDF)

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds

Current oncology reports, 2005-03, Vol.7 (2), p.90-95

2005

Volltextzugriff (PDF)

Pilot study for the use of wearable devices for patients undergoing oral chemotherapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14103-e14103

2020

Volltextzugriff (PDF)

Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma

Clinical genitourinary cancer, 2008-09, Vol.6 (2), p.79-85

2008

Volltextzugriff (PDF)

Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16523-e16523

2018

Volltextzugriff (PDF)

Outcomes in bone predominant (BP) urothelial carcinoma (UC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.441-441

2018

Volltextzugriff (PDF)

Prostate cancer burden at the Uganda Cancer Institute (UCI)

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.246-246

2015

Volltextzugriff (PDF)

Promising systemic therapy for renal cell carcinoma

Current treatment options in oncology, 2005-10, Vol.6 (5), p.357-365

2005

Volltextzugriff (PDF)

HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4578-TPS4578

2016

Volltextzugriff (PDF)

Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.181-181

2017

Volltextzugriff (PDF)

Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D)

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.137-137

2017

Volltextzugriff (PDF)

1 – 25 von 108

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Englisch
(108)

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(49)
Humans
(42)
Male
(27)
Female
(21)
Middle Aged
(21)
Adult
(19)
Oncology
(18)
Aged
(17)
General & Internal Medicine
(12)
Patients
(12)
Medicine, General & Internal
(11)
Animals
(10)
Neoplasms - Drug Therapy
(9)
Aged, 80 And Over
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Treatment Outcome
(8)
Physical Sciences
(7)
Physics
(7)
Tumors
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

The distribution of esophageal cancer patients enrolled in care at the Uganda Cancer Institute by sub-regions, districts and ethnicity

Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer

Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

Upper gastrointestinal diseases in patients for endoscopy in South-Western Uganda

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

Phase 2 Trial of Pemetrexed Disodium and Gemcitabine in Advanced Urothelial Cancer (E4802) : A Trial of the Eastern Cooperative Oncology Group

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds

Pilot study for the use of wearable devices for patients undergoing oral chemotherapy

Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma

Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC)

Outcomes in bone predominant (BP) urothelial carcinoma (UC)

Prostate cancer burden at the Uganda Cancer Institute (UCI)

Promising systemic therapy for renal cell carcinoma

HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)

Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial

Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D)

Aktive Filter

Suchergebnisse filtern